Lopinavir/ritonavir

Lopinavir/ritonavir
Combination of
Lopinavir	Protease inhibitor
Ritonavir	Protease inhibitor (pharmacokinetic booster)
Clinical data
Trade names	Kaletra, Aluvia
AHFS/Drugs.com	Monograph
MedlinePlus	a602015
License data	US DailyMed: Kaletra;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AR10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	369372-47-4 ;
PubChem CID	11979606;
KEGG	D02498;
NIAID ChemDB	003688;
CompTox Dashboard (EPA)	DTXSID30190428 ;
	(what is this?) (verify)

Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a fixed-dose combination antiretroviral medication for the treatment and prevention of HIV/AIDS. It combines lopinavir with a low dose of ritonavir. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth as a tablet, capsule, or solution.

Common side effects include diarrhea, vomiting, feeling tired, headaches, and muscle pains. Severe side effects may include pancreatitis, liver problems, and high blood sugar. It is commonly used in pregnancy and it appears to be safe. Both medications are HIV protease inhibitors. Ritonavir functions by slowing down the breakdown of lopinavir.

Lopinavir/ritonavir as a combination medication was approved for use in the United States in 2000. It is on the World Health Organization's List of Essential Medicines.